<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1237">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132272</url>
  </required_header>
  <id_info>
    <org_study_id>201503IMAD</org_study_id>
    <secondary_id>CIV-16-02-014668</secondary_id>
    <nct_id>NCT03132272</nct_id>
  </id_info>
  <brief_title>Immunoadsorption for Treatment of Alzheimer's Disease</brief_title>
  <acronym>IMAD</acronym>
  <official_title>Efficacy of Immunoadsorption for Treatment of Persons With Alzheimer Dementia and Agonistic Autoantibodies Against alpha1A-adrenoceptor (IMAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy of immunoadsorption for treatment of persons with Alzheimer dementia and agonistic&#xD;
      autoantibodies against alpha1A-adrenoceptor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The IMAD trial outlined aims to ascertain whether the positive effects of immunoadsorption&#xD;
      (IA) on slowing down dementia progression, shown in a pilot trial, can be replicated in a&#xD;
      slightly larger number of subjects and to comprehensively investigate the effects by a&#xD;
      combination of brain and vessel imaging along with cognitive tests and further&#xD;
      state-of-the-art cardiovascular, cerebrovascular and laboratory examinations. If the trial&#xD;
      results underpin the hypothesis that IA effectively counteracts pathophysiological&#xD;
      impairments and dementia-related cognitive decline, it may open up a new treatment approach&#xD;
      against dementia, namely the reversal or avoidance of further vascular damage by the removal&#xD;
      of agonistic autoantibodies (agAAB) in agAAB-positive persons.&#xD;
&#xD;
      The aim of this study is (beside of safety) to demonstrate the stop of the vascular&#xD;
      remodeling and cognition decline by immunoadsorption, a therapeutic method which is well&#xD;
      established in cardiology and nephrology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow recruiting, difficulties in finding eligible patients&#xD;
  </why_stopped>
  <start_date type="Actual">September 15, 2016</start_date>
  <completion_date type="Actual">October 12, 2020</completion_date>
  <primary_completion_date type="Actual">October 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in cerebral blood flow, estimated by Arterial Spin Labeling MRI</measure>
    <time_frame>Measurement at 4 times over a 12 months period: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA</time_frame>
    <description>Measurement of cerebral blood flow and evaluation of changes between baseline and condition after intervention over a 12 months period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognition (changes/improvement/impairment)</measure>
    <time_frame>Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA</time_frame>
    <description>Measurement by Alzheimer's Disease Assessment Scale (ADAS-cog)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition (changes/improvement/impairment)</measure>
    <time_frame>Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA</time_frame>
    <description>Measurement by Mini Mental Status Examination-2 (MMSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition (changes/improvement/impairment)</measure>
    <time_frame>Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA</time_frame>
    <description>Measurement by California Verbal Learning Test (CVLT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition (changes/improvement/impairment)</measure>
    <time_frame>Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA</time_frame>
    <description>Measurement by Benton Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular effects</measure>
    <time_frame>Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA</time_frame>
    <description>Left ventricular ejection fraction (LVEF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular effects</measure>
    <time_frame>Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA</time_frame>
    <description>Endothelial function: measurement by Endo-PAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular effects</measure>
    <time_frame>Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA</time_frame>
    <description>Arterial stiffness: measurement by Endo-PAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular effects</measure>
    <time_frame>Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA</time_frame>
    <description>Arterial stiffness: measurement by Mobil-O-Graph (pulse wave analysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular effects</measure>
    <time_frame>Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA</time_frame>
    <description>Oxygen saturation: transcutaneous oxygen pressure examinations by PRÃ‰CISE 8008, Medicap</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA</time_frame>
    <description>Nephrosonography: position, size and surface of kidneys, echogenicity, presence and assessment of cysts and tumors, calcifications, nephroliths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Measurement at 4 times: before IA (= baseline), 1 month after IA, 6 months after IA, 12 months after IA</time_frame>
    <description>Estimated glomerular Filtration rate (eGFR) using Modification of Diet in Renal Disease (MDRD) formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters in liquor associated with Alzheimer's disease</measure>
    <time_frame>Measurement at 2 times: before IA (= baseline) and 12 months after IA</time_frame>
    <description>Measurement of beta-amyloid and tau species concentrations in liquor (optional; only if subjects gave informed consent in lumbar puncture)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum analytics</measure>
    <time_frame>12 months</time_frame>
    <description>analysis of agonistic autoantibodies against alpha1A adrenoceptor and measurement of different biomarkers, metabolites associated with Alzheimer's disease in blood samples</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Alzheimer Dementia</condition>
  <arm_group>
    <arm_group_label>Immunoadsorption with Globaffin for Alzheimer Dementia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunoadsorption with Globaffin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Immunoadsorption with Globaffin</intervention_name>
    <description>Immunoadsorption for treatment of persons with Alzheimer Dementia</description>
    <arm_group_label>Immunoadsorption with Globaffin for Alzheimer Dementia</arm_group_label>
    <other_name>agonistic autoantibodies</other_name>
    <other_name>alpha1A-adrenoceptor</other_name>
    <other_name>Globaffin adsorber columns</other_name>
    <other_name>ADAsorb apheresis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  55-85 years of age&#xD;
&#xD;
          -  Diagnosis of Alzheimer's disease&#xD;
&#xD;
          -  Presence of agAAB against alpha1-adrenoceptor&#xD;
&#xD;
          -  Mini mental state examination (MMSE) score between 19 and 26&#xD;
&#xD;
          -  Written informed consent given&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Haemanalysis:&#xD;
&#xD;
               -  Presence of autoantibodies against the N-methyl-D-aspartate (NMDA) receptor&#xD;
&#xD;
               -  Defective blood coagulation at time of inclusion&#xD;
&#xD;
               -  Severe protein deficiency disorders&#xD;
&#xD;
               -  manifest Vitamin/Folic acid deficiency (substitution allowed)&#xD;
&#xD;
          -  Active infectious disease, or signs of ongoing infection with C-reactive protein (CRP)&#xD;
             &gt;10mmol/L&#xD;
&#xD;
          -  Impaired renal function (serum creatinine &gt;220 Î¼mol/L)&#xD;
&#xD;
          -  Any disease requiring immunosuppressive drugs or therapeutic antibodies&#xD;
&#xD;
          -  Non curative treated malignant disease or another life-threatening disease with poor&#xD;
             prognosis (survival less than 2 years), except for basal-cell carcinoma&#xD;
&#xD;
          -  Unstable angina pectoris, atrioventricular block (AV block) 2./3. degree or&#xD;
             symptomatic sick sinus syndrome without implanted pacemaker, history of myocardial&#xD;
             infarct, bypass or other revascularization measures, valvular heart defect (â‰¥ 2.&#xD;
             Degree)&#xD;
&#xD;
          -  Severely reduced left ventricular systolic function (LVEF &lt; 30%) and/or heart failure&#xD;
             symptoms according to New York Heart Association (NYHA) class III/IV&#xD;
&#xD;
          -  Clinical manifestation of arterial disease, vascular surgery: No Arteria Carotis&#xD;
             Interna (ACI) Stenosis &gt; 60%, peripheral artery occlusive disease (PAOD) &gt; IIb,&#xD;
             NASCET, no clinical manifest apparent stroke in anamnesis, MRI: no diffusion disorder,&#xD;
             no expired territorial stroke&#xD;
&#xD;
          -  Endocrine disorder excluding diabetes mellitus&#xD;
&#xD;
          -  Severe hepatic damages (CHILD-Score &lt; 4)&#xD;
&#xD;
          -  Severe mental disorders (bipolar disorder, schizophrenia, depression) requiring&#xD;
             treatment&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Drug therapy against dementia since less than 3 months&#xD;
&#xD;
          -  Psychopharmacological drug therapy since less than 3 months&#xD;
&#xD;
          -  Dialysis requirement&#xD;
&#xD;
          -  MRI contraindications (e.g. heart pacemaker)&#xD;
&#xD;
          -  Legal tutelage&#xD;
&#xD;
          -  Previous treatments with IA or immunoglobulin&#xD;
&#xD;
          -  Inability to undergo the study procedure (IA on five consecutive days with subsequent&#xD;
             Immunoglobulin G (IgG) substitution)&#xD;
&#xD;
          -  treatment with angiotensin-converting-enzyme inhibitors (ACE inhibitors) during the IA&#xD;
             (angiotensin receptor blockers (AT-blockers) possible)&#xD;
&#xD;
          -  Participation in any other clinical/interventional study within less than 30 days&#xD;
             prior to screening date&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus DÃ¶rr, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medicine Greifswald</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medicine Greifswald</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADAsorb apheresis</keyword>
  <keyword>Globaffin adsorber</keyword>
  <keyword>Agonistic Autoantibodies</keyword>
  <keyword>Immunoadsorption</keyword>
  <keyword>Alzheimer Dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

